Efficacy of Anakinra in Pericarditis: A Systematic Review.

Autor:	Cheema AH; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Chaludiya K; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Khalid M; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Nwosu M; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Konka S; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Agyeman WY; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Bisht A; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Gopinath A; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Arcia Franchini AP; Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2022 Oct 03; Vol. 14 (10), pp. e29862. Date of Electronic Publication: 2022 Oct 03 (Print Publication: 2022).
DOI:	10.7759/cureus.29862
Abstrakt:	Inflammation of the pericardium is referred to as pericarditis, which can cause sharp chest pain and has a high chance of recurrence even after treatment. This review will explore anakinra, which is an interleukin-1 receptor antagonist, as a potential new treatment for pericarditis. The systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines by searching PubMed and GoogleScholar from the years 2012 to 2022. After applying inclusion and exclusion criteria, thorough screening, and quality appraisal, a total of eleven studies were included in the review; eight case reports and three clinical trials. All studies showed that 100 mg/day of anakinra caused a remarkable improvement in patient outcomes. In addition, the pericarditis resolved quicker and had a lower chance of recurrence in comparison to conventional therapy. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Cheema et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu